Figure 1

High GFI1 expression associates with raised FLT3 expression and inferior survival in CN-AML patients. (A) Scatter plot representation of GFI1 expression for patient samples from the whole Verhaak et al.¹⁹ dataset (WHOLE AML) or selected on the basis of having a normal karyotype (CN-AML). (B) Representation of GFI1 ^low and GFI1 ^high expression boundaries as reported by Hönes et al.¹⁸ (0–5% low expression, 60–100% high expression) and in the present study (0–30% low expression, 70–100% high expression). (C) Kaplan-Meyer representation of overall survival for CN-AML patients from the Verhaak et al.¹⁹ dataset subdivided in low and high GFI1 expressers. (D) Box plot representing FLT3 transcript levels in GFI1 ^low versus GFI1 ^high CN-AML patient samples. Statistical significance: ***< 0.001, **< 0.01, *< 0.05. (E) Kaplan-Meyer estimates of overall survival for GFI1 ^low and GFI1 ^high FLT3-WT CN-AML samples in comparison with FLT3-ITD CN-AML patients from the Verhaak et al.¹⁹ dataset. (F) Boxplot depicting FLT3 transcript levels in GFI1 ^low and GFI1 ^high FLT3-WT CN-AML in comparison with FLT3-ITD CN-AML samples.